FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3146540218> ?p ?o ?g. }

• W3146540218 endingPage "1652" @default.
• W3146540218 startingPage "1652" @default.
• W3146540218 abstract "Background Crohn’s disease is often treated with glucocorticoids or mesalamine. We compared the efficacy and safety of controlled-ileal-release budesonide capsules and slow-release mesalamine tablets in patients with active Crohn’s disease affecting the ileum, the ascending colon, or both. Methods In a double-blind, multicenter trial, we enrolled 182 patients with scores of 200 to 400 on the Crohn’s Disease Activity Index (with higher scores indicating greater disease activity) and randomly assigned 93 to receive 9 mg of budesonide once daily and 89 to receive 2 g of mesalamine twice daily for 16 weeks. The primary efficacy variable was clinical remission, defined as a score of 150 or less on the Crohn’s Disease Activity Index. Results In the analysis of all patients who received at least one dose of study drug, the rates of remission after 8 weeks of treatment were 69 percent in the budesonide group and 45 percent in the mesalamine group (P=0.001); the respective rates after 16 weeks of treatment were 62 percent and 36 percent (P<0.001). Seventy-seven patients in the budesonide group completed the 16 weeks of treatment, as compared with 50 patients in the mesalamine group (P<0.001). The numbers of patients with adverse events were similar in the two groups, but those assigned to budesonide had fewer severe adverse events. Among patients who completed 16 weeks of treatment, the morning plasma cortisol value was normal in 67 percent of budesonide-treated patients and 83 percent of mesalamine-treated patients (P=0.06); 90 percent and 100 percent, respectively, had normal increases in cortisol in response to cosyntropin (P=0.02). Conclusions In patients with active Crohn’s disease affecting the ileum, the ascending colon, or both, a controlled-ileal-release formulation of budesonide was more effective in inducing remission than a slow-release formulation of mesalamine. (N Engl J Med 1998;339:370-4.)" @default.
• W3146540218 created "2021-04-13" @default.
• W3146540218 date "2001-11-29" @default.
• W3146540218 modified "2023-10-17" @default.
• W3146540218 title "A Comparison of Budesonide and Mesalamine for Active Crohn's Disease" @default.
• W3146540218 cites W1573810982 @default.
• W3146540218 cites W1761355724 @default.
• W3146540218 cites W1976450674 @default.
• W3146540218 cites W1982834592 @default.
• W3146540218 cites W2027812459 @default.
• W3146540218 cites W2043445373 @default.
• W3146540218 cites W2141570612 @default.
• W3146540218 cites W2267316820 @default.
• W3146540218 cites W2315020282 @default.
• W3146540218 cites W2331622494 @default.
• W3146540218 cites W2335853094 @default.
• W3146540218 cites W2340680662 @default.
• W3146540218 cites W2342066803 @default.
• W3146540218 cites W2419090247 @default.
• W3146540218 cites W3112583453 @default.
• W3146540218 doi "https://doi.org/10.1056/nejm200111293452221" @default.
• W3146540218 hasPublicationYear "2001" @default.
• W3146540218 type Work @default.
• W3146540218 sameAs 3146540218 @default.
• W3146540218 citedByCount "45" @default.
• W3146540218 countsByYear W31465402182012 @default.
• W3146540218 countsByYear W31465402182013 @default.
• W3146540218 countsByYear W31465402182014 @default.
• W3146540218 countsByYear W31465402182016 @default.
• W3146540218 crossrefType "journal-article" @default.
• W3146540218 hasBestOaLocation W31465402181 @default.
• W3146540218 hasConcept C126322002 @default.
• W3146540218 hasConcept C2776136866 @default.
• W3146540218 hasConcept C2776804153 @default.
• W3146540218 hasConcept C2779134260 @default.
• W3146540218 hasConcept C2779280984 @default.
• W3146540218 hasConcept C2992200296 @default.
• W3146540218 hasConcept C71924100 @default.
• W3146540218 hasConcept C90924648 @default.
• W3146540218 hasConceptScore W3146540218C126322002 @default.
• W3146540218 hasConceptScore W3146540218C2776136866 @default.
• W3146540218 hasConceptScore W3146540218C2776804153 @default.
• W3146540218 hasConceptScore W3146540218C2779134260 @default.
• W3146540218 hasConceptScore W3146540218C2779280984 @default.
• W3146540218 hasConceptScore W3146540218C2992200296 @default.
• W3146540218 hasConceptScore W3146540218C71924100 @default.
• W3146540218 hasConceptScore W3146540218C90924648 @default.
• W3146540218 hasIssue "22" @default.
• W3146540218 hasLocation W31465402181 @default.
• W3146540218 hasOpenAccess W3146540218 @default.
• W3146540218 hasPrimaryLocation W31465402181 @default.
• W3146540218 hasRelatedWork W1568450052 @default.
• W3146540218 hasRelatedWork W1968474990 @default.
• W3146540218 hasRelatedWork W1982563674 @default.
• W3146540218 hasRelatedWork W1984978920 @default.
• W3146540218 hasRelatedWork W2029403749 @default.
• W3146540218 hasRelatedWork W2072905780 @default.
• W3146540218 hasRelatedWork W2085446880 @default.
• W3146540218 hasRelatedWork W2167194258 @default.
• W3146540218 hasRelatedWork W4237668683 @default.
• W3146540218 hasRelatedWork W4248379340 @default.
• W3146540218 hasVolume "345" @default.
• W3146540218 isParatext "false" @default.
• W3146540218 isRetracted "false" @default.
• W3146540218 magId "3146540218" @default.
• W3146540218 workType "article" @default.